ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-16 08:00:00,2024-10-16T08:00:00-04:00,2024-10-16,Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception,"A total of 12 abstracts, including four Best of Cosmetic Abstracts, demonstrate Allergan Aesthetics' commitment to patient outcomes and detailed insights and understanding of key concerns across differentiated patient segments Insightful panel discussion with Dr. Kavita Mariwalla, ASDS President Elect (2026) and double board-certified dermatologist, on impact of social media on patient experience and expectations when considering aesthetic treatment IRVINE, Calif. , Oct. 16, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will present data highlighting efficacy, safety and patient-reported outcomes across its facial injectable portfolio during the 2024 American Society of Dermatologic Surgery (ASDS) Annual Meeting, October 17-20, 2024 in Orlando, Florida.",prnewswire.com,https://www.prnewswire.com/news-releases/allergan-aesthetics-to-present-new-data-at-2024-american-society-for-dermatologic-surgery-asds-to-showcase-depth-across-facial-aesthetics-and-insight-into-patient-perception-302277332.html,https://images.financialmodelingprep.com/news/allergan-aesthetics-to-present-new-data-at-2024-american-20241016.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-17 18:51:26,2024-10-17T18:51:26-04:00,2024-10-17,AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know,"AbbVie (ABBV) reachead $188.57 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.",zacks.com,https://www.zacks.com/stock/news/2352701/abbvie-abbv-falls-more-steeply-than-broader-market-what-investors-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2352701,https://images.financialmodelingprep.com/news/abbvie-abbv-falls-more-steeply-than-broader-market-what-20241017.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-17 14:15:50,2024-10-17T14:15:50-04:00,2024-10-17,"Calls of the Day: Crowdstrike, Cheniere Energy, 3M, Abbott Labs, Abbvie and Eli Lilly",The Investment Committee debate the latest Calls Of The Day.,youtube.com,https://www.youtube.com/watch?v=MeXhDJbQAYY,https://images.financialmodelingprep.com/news/calls-of-the-day-crowdstrike-cheniere-energy-3m-abbott-20241017.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-17 08:33:00,2024-10-17T08:33:00-04:00,2024-10-17,AbbVie wins FDA nod for infusion treatment for advanced Parkinson's disease,Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson's disease.,marketwatch.com,https://www.marketwatch.com/story/abbvie-says-fda-has-approved-vyalev-as-first-and-only-subcutaneous-24-hour-infusion-for-adults-with-advanced-parkinsons-disease-6ca6d410,https://images.financialmodelingprep.com/news/abbvie-wins-fda-nod-for-infusion-treatment-for-advanced-20241017.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-17 08:00:00,2024-10-17T08:00:00-04:00,2024-10-17,U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease,"VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV reported superior improvement in ""on"" time wi thout troublesome dyskinesia, compared to oral immediate-release carbidopa/levodopa1 VYALEV allows for personalized dosing based on individual needs, morning, day and night NORTH CHICAGO, Ill. , Oct. 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD).",prnewswire.com,https://www.prnewswire.com/news-releases/us-fda-approves-vyalev-foscarbidopa-and-foslevodopa-for-adults-living-with-advanced-parkinsons-disease-302278666.html,https://images.financialmodelingprep.com/news/us-fda-approves-vyalev-foscarbidopa-and-foslevodopa-for-adults-20241017.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-18 19:44:00,2024-10-18T19:44:00-04:00,2024-10-18,BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands),"The Only Product of Its Kind Approved for Use in Four Aesthetic Indications: Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines, Frown Lines, Crow's Feet Lines, and Now Platysma Bands in Adults1-5 With this Approval, BOTOX® Cosmetic is the First and Only Aesthetic Neurotoxin Product to Temporarily Improve the Appearance of Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands) in Adults1-5 IRVINE, Calif. , Oct. 18, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of BOTOX® Cosmetic for temporary improvement in the appearance of moderate to severe vertical bands connecting the jaw and neck (platysma bands) in adults.1 BOTOX® Cosmetic is the first and only product with four aesthetic indication areas: forehead lines, frown lines, crow's feet lines, and now platysma bands, making it the first product of its kind to go beyond the face.1-5  ""Research shows millions of consumers in the U.S. are extremely or very bothered by their platysma bands.6* Until now, treatment options have been limited and with this approval, there is a nonsurgical, injectable option to temporarily improve the look of vertical bands connecting the jaw and neck,"" said Darin J.",prnewswire.com,https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-severe-vertical-bands-connecting-the-jaw-and-neck-platysma-bands-302280924.html,https://images.financialmodelingprep.com/news/botox-cosmetic-onabotulinumtoxina-receives-fda-approval-for-moderate-to-20241018.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-18 10:05:25,2024-10-18T10:05:25-04:00,2024-10-18,AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev,"With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.",zacks.com,https://www.zacks.com/stock/news/2353175/abbvie-secures-fda-approval-for-parkinson-s-disease-drug-vyalev?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2353175,https://images.financialmodelingprep.com/news/abbvie-secures-fda-approval-for-parkinsons-disease-drug-vyalev-20241018.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-18 05:20:00,2024-10-18T05:20:00-04:00,2024-10-18,3 Growth Stocks That Could Be Bargain Buys Right Now,These stocks trade at less than 20 times their estimated future profits.,fool.com,https://www.fool.com/investing/2024/10/18/3-growth-stocks-that-could-be-bargain-buys-right-n/,https://images.financialmodelingprep.com/news/3-growth-stocks-that-could-be-bargain-buys-right-20241018.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-22 07:48:25,2024-10-22T07:48:25-04:00,2024-10-22,AbbVie: Strong Dividends But Humira Disappoints,"Healthcare stocks are both defensive and present a mean reversion opportunity, making them attractive for risk-averse investors. Revenue exposure analysis shows consistent growth trends over 10 years, indicating stability and resilience but downward over 5. Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections.",seekingalpha.com,https://seekingalpha.com/article/4728220-abbvie-strong-dividends-but-humira-disappoints,https://images.financialmodelingprep.com/news/abbvie-strong-dividends-but-humira-disappoints-20241022.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-23 11:38:53,2024-10-23T11:38:53-04:00,2024-10-23,AbbVie: Expect A Beat-And-Raise Q3 2024,"AbbVie will report Q3 2024 results next week and I expect to see a beat-and-raise quarter. The outperformance should be driven by top growth products Skyrizi and Rinvoq, the strong performance of neuroscience and oncology segments and by the return to growth of the aesthetics segment. I also expect the company to increase the full-year revenue guidance by $300-500 million.",seekingalpha.com,https://seekingalpha.com/article/4728635-abbvie-expect-a-beat-and-raise-q3-2024,https://images.financialmodelingprep.com/news/abbvie-expect-a-beatandraise-q3-2024-20241023.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-23 11:08:00,2024-10-23T11:08:00-04:00,2024-10-23,Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,zacks.com,https://www.zacks.com/stock/news/2355947/analysts-estimate-abbvie-abbv-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2355947,https://images.financialmodelingprep.com/news/analysts-estimate-abbvie-abbv-to-report-a-decline-in-20241023.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-23 10:05:16,2024-10-23T10:05:16-04:00,2024-10-23,AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",zacks.com,https://www.zacks.com/stock/news/2355592/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2355592,https://images.financialmodelingprep.com/news/abbvie-inc-abbv-is-attracting-investor-attention-here-is-20241023.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-23 08:10:00,2024-10-23T08:10:00-04:00,2024-10-23,My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 12 Buys,"September's investment activity was minimal, with $1,000 invested mainly in Business Development Companies, while I traveled through Hungary, Albania, and Oman. Traveling highlighted the benefits of lower living costs abroad, reinforcing the idea that financial independence is about where and how you live. My September dividend income hit a record $1,141, driven by Ares Capital and MidCap Financial, with a focus on high-yield BDCs.",seekingalpha.com,https://seekingalpha.com/article/4728457-my-dividend-stock-portfolio-new-september-dividend-record-100-holdings-with-12-buys,https://images.financialmodelingprep.com/news/my-dividend-stock-portfolio-new-september-dividend-record-100-20241023.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-23 06:50:00,2024-10-23T06:50:00-04:00,2024-10-23,Beat the Nasdaq With This Cash-Gushing Dividend Stock,The company is performing well despite recently losing its biggest growth driver.,fool.com,https://www.fool.com/investing/2024/10/23/beat-the-nasdaq-with-this-cash-gushing-dividend-st/,https://images.financialmodelingprep.com/news/beat-the-nasdaq-with-this-cashgushing-dividend-stock-20241023.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-24 18:50:33,2024-10-24T18:50:33-04:00,2024-10-24,AbbVie (ABBV) Outperforms Broader Market: What You Need to Know,"In the closing of the recent trading day, AbbVie (ABBV) stood at $189.65, denoting a +0.94% change from the preceding trading day.",zacks.com,https://www.zacks.com/stock/news/2357268/abbvie-abbv-outperforms-broader-market-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2357268,https://images.financialmodelingprep.com/news/abbvie-abbv-outperforms-broader-market-what-you-need-to-20241024.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-24 11:30:00,2024-10-24T11:30:00-04:00,2024-10-24,AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions,"Companies will discover and develop novel targets for the potential treatment of neuropsychiatric conditions  New discovery program builds upon nearly two decades of partnership between AbbVie and Gedeon Richter NORTH CHICAGO, Ill. and BUDAPEST, Hungary , Oct. 24, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gedeon Richter Plc.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-and-gedeon-richter-announce-new-collaboration-for-the-discovery-and-development-of-novel-targets-for-neuropsychiatric-conditions-302284729.html,https://images.financialmodelingprep.com/news/abbvie-and-gedeon-richter-announce-new-collaboration-for-the-20241024.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-25 13:26:32,2024-10-25T13:26:32-04:00,2024-10-25,"Final Trades: Tesla, Sweetgreen, AbbVie and Digital Realty",CNBC's Investment Committee join 'Halftime Report' to give you their top stocks to watch.,youtube.com,https://www.youtube.com/watch?v=qOrBIqG2tzA,https://images.financialmodelingprep.com/news/final-trades-tesla-sweetgreen-abbvie-and-digital-realty-20241025.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-25 10:20:39,2024-10-25T10:20:39-04:00,2024-10-25,Curious about AbbVie (ABBV) Q3 Performance? Explore Wall Street Estimates for Key Metrics,"Looking beyond Wall Street's top -and-bottom-line estimate forecasts for AbbVie (ABBV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.",zacks.com,https://www.zacks.com/stock/news/2357641/curious-about-abbvie-abbv-q3-performance-explore-wall-street-estimates-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2357641,https://images.financialmodelingprep.com/news/curious-about-abbvie-abbv-q3-performance-explore-wall-street-20241025.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-25 10:20:23,2024-10-25T10:20:23-04:00,2024-10-25,Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?,"Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.",zacks.com,https://www.zacks.com/stock/news/2357873/should-abbvie-stock-be-in-your-portfolio-pre-q3-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2357873,https://images.financialmodelingprep.com/news/should-abbvie-stock-be-in-your-portfolio-preq3-earnings-20241025.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-25 08:30:00,2024-10-25T08:30:00-04:00,2024-10-25,3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees,These stocks yield between 2.8% and 3.3% in dividends.,fool.com,https://www.fool.com/investing/2024/10/25/3-high-yielding-dividend-stocks-that-can-be-ideal/,https://images.financialmodelingprep.com/news/3-highyielding-dividend-stocks-that-can-be-ideal-buys-20241025.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-26 07:30:00,2024-10-26T07:30:00-04:00,2024-10-26,3 Dividend Growth Stocks You Can Buy and Hold Forever,These healthcare stocks have fantastic dividend track records.,fool.com,https://www.fool.com/investing/2024/10/26/3-dividend-growth-stocks-you-can-buy-and-hold-fore/,https://images.financialmodelingprep.com/news/3-dividend-growth-stocks-you-can-buy-and-hold-20241026.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-28 13:10:38,2024-10-28T13:10:38-04:00,2024-10-28,Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?,"Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.",zacks.com,https://www.zacks.com/stock/news/2358849/will-these-5-big-drug-stocks-surpass-q3-earnings-forecasts?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview_esp-2358849,https://images.financialmodelingprep.com/news/will-these-5-big-drug-stocks-surpass-q3-earnings-20241028.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-28 08:21:51,2024-10-28T08:21:51-04:00,2024-10-28,AbbVie to buy Alzheimer's therapy developer Aliada Therapeutics for $1.4 bln,"U.S. drugmaker AbbVie said on Monday it would acquire Aliada Therapeutics for $1.4 billion in cash, gaining access to the therapy developer's Alzheimer's disease drug candidate.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-buy-alzheimers-therapy-developer-aliada-therapeutics-14-bln-2024-10-28/,https://images.financialmodelingprep.com/news/abbvie-to-buy-alzheimers-therapy-developer-aliada-therapeutics-for-20241028.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-28 08:00:00,2024-10-28T08:00:00-04:00,2024-10-28,"AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline","Aliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's disease Acquisition also allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscience NORTH CHICAGO, Ill. and BOSTON , Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-to-acquire-aliada-therapeutics-strengthening-focus-in-alzheimers-disease-and-neuroscience-pipeline-302288180.html,https://images.financialmodelingprep.com/news/abbvie-to-acquire-aliada-therapeutics-strengthening-focus-in-alzheimers-20241028.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-29 12:15:17,2024-10-29T12:15:17-04:00,2024-10-29,AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings,AbbVie Inc ABBV will be reporting its third-quarter earnings on Wednesday. Wall Street expects $2.92 in EPS and $14.28 billion in revenues as the company reports before market hours.,benzinga.com,https://www.benzinga.com/general/biotech/24/10/41605057/abbvie-chart-reflects-bearish-signals-ahead-of-q3-earnings,https://images.financialmodelingprep.com/news/abbvie-chart-reflects-bearish-signals-ahead-of-q3-earnings-20241029.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 18:25:42,2024-10-30T18:25:42-04:00,2024-10-30,AbbVie: 3 Positives From The Earnings Report,"It is no surprise investors have responded positively to AbbVie's latest results considering revenue growth, earnings outlook upgrade, and dividend increase. The company also has growth catalysts in place, especially with its treatment for Parkinson's disease showing positive trial results. However, its P/E is high for now, and its recent acquisition of Aliada Therapeutics risks being a drag on earnings.",seekingalpha.com,https://seekingalpha.com/article/4731152-abbvie-3-positives-from-earnings-report,https://images.financialmodelingprep.com/news/abbvie-3-positives-from-the-earnings-report-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 14:26:11,2024-10-30T14:26:11-04:00,2024-10-30,AbbVie Inc. (ABBV) Q3 2024 Earnings Call Transcript,"AbbVie Inc. (NYSE:ABBV ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Liz Shea - Senior Vice President, Investor Relations Robert A. Michael - C hief Executive Officer Jeffrey R.",seekingalpha.com,https://seekingalpha.com/article/4731046-abbvie-inc-abbv-q3-2024-earnings-call-transcript,https://images.financialmodelingprep.com/news/abbvie-inc-abbv-q3-2024-earnings-call-transcript-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 13:05:22,2024-10-30T13:05:22-04:00,2024-10-30,"AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View",ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.,zacks.com,https://www.zacks.com/stock/news/2360933/abbvie-trumps-q3-earnings-sales-estimates-raises-24-eps-view?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2360933,https://images.financialmodelingprep.com/news/abbvie-trumps-q3-earnings-sales-estimates-raises-24-eps-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 11:31:15,2024-10-30T11:31:15-04:00,2024-10-30,"Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics","Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",zacks.com,https://www.zacks.com/stock/news/2360829/compared-to-estimates-abbvie-abbv-q3-earnings-a-look-at-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2360829,https://images.financialmodelingprep.com/news/compared-to-estimates-abbvie-abbv-q3-earnings-a-look-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 10:17:40,2024-10-30T10:17:40-04:00,2024-10-30,"AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth","On Wednesday, AbbVie Inc.  ABBV reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the consensus of $2.92.",benzinga.com,https://www.benzinga.com/general/biotech/24/10/41626490/abbvie-tops-q3-expectations-as-skyrizi-rinvoq-drive-growth,https://images.financialmodelingprep.com/news/abbvie-tops-q3-expectations-as-skyrizi-rinvoq-drive-growth-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 09:51:21,2024-10-30T09:51:21-04:00,2024-10-30,AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates,"AbbVie (ABBV) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.95 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2360394/abbvie-abbv-surpasses-q3-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2360394,https://images.financialmodelingprep.com/news/abbvie-abbv-surpasses-q3-earnings-and-revenue-estimates-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 08:34:00,2024-10-30T08:34:00-04:00,2024-10-30,"AbbVie Stock Rises After Earnings Beat, Dividend Hike",The drug maker increased dividend by 5.8% to $1.64 per share.,barrons.com,https://www.barrons.com/articles/abbvie-earnings-dividend-stock-price-cd2c85a3,https://images.financialmodelingprep.com/news/abbvie-stock-rises-after-earnings-beat-dividend-hike-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 07:52:44,2024-10-30T07:52:44-04:00,2024-10-30,"AbbVie raises 2024 profit forecast on strong sales of key drugs Skyrizi, Rinvoq",AbbVie raised its annual profit forecast on Wednesday after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-2024-profit-forecast-strong-sales-key-drugs-skyrizi-rinvoq-2024-10-30/,https://images.financialmodelingprep.com/news/abbvie-raises-2024-profit-forecast-on-strong-sales-of-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 07:38:00,2024-10-30T07:38:00-04:00,2024-10-30,AbbVie Reports Third-Quarter 2024 Financial Results,"Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of $0.04 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers Third-Quarter Net Revenues of $14.460 Billion, an Increase of 3.8 Percent on a Reported Basis or 4.9 Percent on an Operational Basis  Third -Quarter Global Net Revenues from the Immunology Portfolio Were $7.046 Billion, an Increase of 3.9 Percent on a Reported Basis, or 4.8 Percent on an Operational Basis; Global Humira Net Revenues Were $2.227 Billion; Global Skyrizi Net Revenues Were $3.205 Billion; Global Rinvoq Net Revenues Were $1.614 Billion   Third -Quarter Global Net Revenues from the Oncology Portfolio Were $1.687 Billion, an Increase of 11.6 Percent on a Reported Basis, or 13.0 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $828 Million; Global Venclexta Net Revenues Were $677 Million   Third -Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.363 Billion, an Increase of 15.6 Percent on a Reported Basis, or 16.0 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $848 Million; Global Vraylar Net Revenues Were $875 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $445 Million   Third -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.239 Billion, a Decrease of 0.1 Percent on a Reported Basis, or an Increase of 1.8 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $671 Million; Global Juvederm Net Revenues Were $258 Million   Successfully Completed Acquisition of Cerevel, Adding Pipeline of Highly Complementary Assets to AbbVie's Existing Neuroscience Portfolio  Raises 2024 Adjusted Diluted EPS Guidance Range from $10.67 - $10.87 to $10.90 - $10.94, which Includes an Unfavorable Impact of $0.64 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2024  Announces 2025 Dividend Increase of 5.8 Percent, Beginning with Dividend Payable in February 2025 NORTH CHICAGO, Ill. , Oct. 30, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2024.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-reports-third-quarter-2024-financial-results-302290774.html,https://images.financialmodelingprep.com/news/abbvie-reports-thirdquarter-2024-financial-results-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-30 07:00:00,2024-10-30T07:00:00-04:00,2024-10-30,3 Dividend Growth Stocks to Buy and Never Sell,These 3 dividend growth stocks have crushed the market and show no signs of slowing down.,fool.com,https://www.fool.com/investing/2024/10/30/3-dividend-growth-stocks-to-buy-and-never-sell/,https://images.financialmodelingprep.com/news/3-dividend-growth-stocks-to-buy-and-never-sell-20241030.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-31 08:00:00,2024-10-31T08:00:00-04:00,2024-10-31,AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics,Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer,globenewswire.com,https://www.globenewswire.com/news-release/2024/10/31/2972538/0/en/AbbVie-and-EvolveImmune-Therapeutics-Announce-Collaboration-and-Option-to-License-Agreement-to-Develop-Next-Generation-Cancer-Biotherapeutics.html,https://images.financialmodelingprep.com/news/abbvie-and-evolveimmune-therapeutics-announce-collaboration-and-optiontolicense-agreement-20241031.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-31 08:00:00,2024-10-31T08:00:00-04:00,2024-10-31,AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics,"Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill. and BRANFORD, Conn.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-and-evolveimmune-therapeutics-announce-collaboration-and-option-to-license-agreement-to-develop-next-generation-cancer-biotherapeutics-302290649.html,https://images.financialmodelingprep.com/news/abbvie-and-evolveimmune-therapeutics-announce-collaboration-and-optiontolicense-agreement-to-20241031.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-10-31 05:30:00,2024-10-31T05:30:00-04:00,2024-10-31,5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs,It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.,fool.com,https://www.fool.com/investing/2024/10/31/5-dividend-stocks-to-double-up-on-right-now/,https://images.financialmodelingprep.com/news/5-dividend-stocks-to-double-up-on-right-now-20241031.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-01 08:46:09,2024-11-01T08:46:09-04:00,2024-11-01,5 Stocks That Recently Announced Dividend Hikes,"Investors may keep a tab on stocks like COP, BERY, HII, ABBV and ASB, which have lately hiked their dividend payments.",zacks.com,https://www.zacks.com/stock/news/2362395/5-stocks-that-recently-announced-dividend-hikes?cid=CS-STOCKNEWSAPI-FT-analyst_blog|investment_ideas-2362395,https://images.financialmodelingprep.com/news/5-stocks-that-recently-announced-dividend-hikes-20241101.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-04 07:15:05,2024-11-04T07:15:05-05:00,2024-11-04,High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight,The story with AbbVie NYSE: ABBV in 2024 is that it fell off a patent cliff but survived. It survived and continues to thrive because of its strengths in its core immunology portfolio and diversification efforts.,marketbeat.com,https://www.marketbeat.com/originals/high-yield-abbvie-gains-momentum-a-20-upside-is-in-sight/,https://images.financialmodelingprep.com/news/highyield-abbvie-gains-momentum-a-20-upside-is-in-20241104.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-05 10:05:16,2024-11-05T10:05:16-05:00,2024-11-05,Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?,"AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",zacks.com,https://www.zacks.com/stock/news/2364192/is-most-watched-stock-abbvie-inc-abbv-worth-betting-on-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2364192,https://images.financialmodelingprep.com/news/is-mostwatched-stock-abbvie-inc-abbv-worth-betting-on-20241105.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-07 17:50:15,2024-11-07T17:50:15-05:00,2024-11-07,Dividend Watch: Three Companies Boosting Quarterly Payouts,"Earnings season continues to move at a rapid pace, with many companies reporting daily. And recently, these three companies delivered news of higher dividend payouts.",zacks.com,https://www.zacks.com/commentary/2366798/dividend-watch-three-companies-boosting-quarterly-payouts?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2366798,https://images.financialmodelingprep.com/news/dividend-watch-three-companies-boosting-quarterly-payouts-20241107.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-07 12:40:39,2024-11-07T12:40:39-05:00,2024-11-07,RHHBY or ABBV: Which Is the Better Value Stock Right Now?,Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Roche Holding AG (RHHBY) or AbbVie (ABBV). But which of these two stocks offers value investors a better bang for their buck right now?,zacks.com,https://www.zacks.com/stock/news/2366649/rhhby-or-abbv-which-is-the-better-value-stock-right-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_3-2366649,https://images.financialmodelingprep.com/news/rhhby-or-abbv-which-is-the-better-value-stock-20241107.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-07 08:00:00,2024-11-07T08:00:00-05:00,2024-11-07,Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day,"Last Year, BOTOX® Cosmetic Day Set the Record for the Most BOTOX® Cosmetic Gift Cards Sold in a Single Day1 This Year, the Excitement Continues with New Offers to Refer a Friend Plus the Best-Selling Buy-One-Get-One (BOGO) Free Gift Card Offer Join Allē Today to Take Advantage of Exclusive Offers IRVINE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the sixth annual BOTOX® Cosmetic Day will be Wednesday, November 20.",prnewswire.com,https://www.prnewswire.com/news-releases/allergan-aesthetics-celebrates-annual-botox-cosmetic-onabotulinumtoxina-day-302298114.html,https://images.financialmodelingprep.com/news/allergan-aesthetics-celebrates-annual-botox-cosmetic-onabotulinumtoxina-day-20241107.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-08 10:36:26,2024-11-08T10:36:26-05:00,2024-11-08,Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?,"When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?",zacks.com,https://www.zacks.com/stock/news/2367388/wall-street-bulls-look-optimistic-about-abbvie-abbv-should-you-buy?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|average_broker_rating-2367388,https://images.financialmodelingprep.com/news/wall-street-bulls-look-optimistic-about-abbvie-abbv-should-20241108.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-08 10:06:39,2024-11-08T10:06:39-05:00,2024-11-08,Top 3 stocks to buy after Fed's 25-basis-point rate cut,US stocks remain resilient following the Federal Reserve's decision to lower its key interest rate by another 25 basis points on Thursday. According to the post-meeting statement: The Committee judges that the risks of achieving its employment and inflation goals are roughly in balance.,invezz.com,https://invezz.com/news/2024/11/08/top-3-stocks-to-buy-after-feds-25-basis-point-rate-cut/,https://images.financialmodelingprep.com/news/top-3-stocks-to-buy-after-feds-25basispoint-rate-20241108.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-08 05:00:00,2024-11-08T05:00:00-05:00,2024-11-08,2 Dividend Kings That Would Have Doubled Your Money in 5 Years,You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.,fool.com,https://www.fool.com/investing/2024/11/08/2-dividend-kings-that-would-have-doubled-your-mone/,https://images.financialmodelingprep.com/news/2-dividend-kings-that-would-have-doubled-your-money-20241108.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-09 05:48:00,2024-11-09T05:48:00-05:00,2024-11-09,My Favorite Dividend King to Buy in November,This Dividend King truly wears the crown.,fool.com,https://www.fool.com/investing/2024/11/09/abbvie/,https://images.financialmodelingprep.com/news/my-favorite-dividend-king-to-buy-in-november-20241109.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-10 09:30:00,2024-11-10T09:30:00-05:00,2024-11-10,3 Spectacular High-Yield Dividend Stocks to Buy in November,High yields aren't a warning indicator with these three stocks.,fool.com,https://www.fool.com/investing/2024/11/10/spectacular-high-yield-dividend-stocks-to-buy-in/,https://images.financialmodelingprep.com/news/3-spectacular-highyield-dividend-stocks-to-buy-in-november-20241110.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 19:23:25,2024-11-11T19:23:25-05:00,2024-11-11,"Final Trades: Lyft, Meta, United States Oil Fund & Abbvie",(OPTIMIZED VIDEO SPECIFIC DESCRIPTION),youtube.com,https://www.youtube.com/watch?v=_x58wbqh7s8,https://images.financialmodelingprep.com/news/final-trades-lyft-meta-united-states-oil-fund-abbvie-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 18:45:29,2024-11-11T18:45:29-05:00,2024-11-11,AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings,"I review both AbbVie and Pfizer's recent earnings reports via the window of dividends following Peter Lynch's wisdom. Lynch's insights into dividend stocks are often in the shadow of his reputation as a legendary growth investor. These insights, when overlooked, are an unfortunate loss for dividend investors.",seekingalpha.com,https://seekingalpha.com/article/4736164-abbvie-and-pfizer-q3-dividend-checkup-post-earnings,https://images.financialmodelingprep.com/news/abbvie-and-pfizer-q3-dividend-checkup-postearnings-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 17:00:00,2024-11-11T17:00:00-05:00,2024-11-11,Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade),"AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. There are three significant reasons for optimism from here. However, the dividend yield is near its lowest point in six years; it may pay to wait for another dip.",seekingalpha.com,https://seekingalpha.com/article/4735413-is-abbvie-still-a-strong-buy-after-fantastic-gains-abbv-stock,https://images.financialmodelingprep.com/news/is-abbvie-still-a-strong-buy-after-fantastic-gains-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 15:50:34,2024-11-11T15:50:34-05:00,2024-11-11,AbbVie Stock: Keep Calm And Buy The Dip,AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a buying opportunity. Dividend yield and robust drug pipeline are bullish going forward.,seekingalpha.com,https://seekingalpha.com/article/4736134-abbvie-stock-keep-calm-and-buy-the-dip,https://images.financialmodelingprep.com/news/abbvie-stock-keep-calm-and-buy-the-dip-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 15:22:46,2024-11-11T15:22:46-05:00,2024-11-11,Why AbbVie Stock Was Getting Mashed on Monday,A splashy recent acquisition by the company might not be panning out.,fool.com,https://www.fool.com/investing/2024/11/11/why-abbvie-stock-was-getting-mashed-on-monday/,https://images.financialmodelingprep.com/news/why-abbvie-stock-was-getting-mashed-on-monday-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 13:32:17,2024-11-11T13:32:17-05:00,2024-11-11,AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?,"AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, an experimental treatment for schizophrenia. This setback is notable as AbbVie had invested $8.",invezz.com,https://invezz.com/news/2024/11/11/abbvie-stock-drops-12-on-schizophrenia-drug-setback-should-you-buy-the-dip/,https://images.financialmodelingprep.com/news/abbvie-stock-drops-12-on-schizophrenia-drug-setback-should-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 13:06:15,2024-11-11T13:06:15-05:00,2024-11-11,Trade Tracker: Jim Lebenthal buys more Abbvie,"Jim Lebenthal, chief equity strategist at Cerity Partners, joins CNBC's 'Halftime Report' to discuss why he's buying more of the pharma stock on this dip.",youtube.com,https://www.youtube.com/watch?v=a2Mjyiqz4HM,https://images.financialmodelingprep.com/news/trade-tracker-jim-lebenthal-buys-more-abbvie-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 12:51:56,2024-11-11T12:51:56-05:00,2024-11-11,"AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated","On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.",benzinga.com,https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappr,https://images.financialmodelingprep.com/news/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 12:45:39,2024-11-11T12:45:39-05:00,2024-11-11,AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint,Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of Phase 2 clinical trials.,investopedia.com,https://www.investopedia.com/abbvie-stock-sinks-after-schizophrenia-drug-trials-disappoint-8743057,https://images.financialmodelingprep.com/news/abbvie-stock-sinks-after-schizophrenia-drug-trials-disappoint-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 11:49:14,2024-11-11T11:49:14-05:00,2024-11-11,AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver,"Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of competitor Cobenfy in clinical trials in schizophrenia patients. Emraclidine was the main reason AbbVie acquired Cerevel for $8.7 billion, and I expect a substantial impairment charge on this deal.",seekingalpha.com,https://seekingalpha.com/article/4736064-abbvie-emraclidines-failure-eliminates-an-important-growth-driver,https://images.financialmodelingprep.com/news/abbvie-emraclidines-failure-eliminates-an-important-growth-driver-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 11:03:05,2024-11-11T11:03:05-05:00,2024-11-11,AbbVie sheds $38bn in value after failing schizophrenia drug trials,Pharma giant AbbVie Inc has disclosed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives. The treatment did not show a significant reduction in the mental illness' symptoms compared to a placebo.,proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1060333,https://images.financialmodelingprep.com/news/abbvie-sheds-38bn-in-value-after-failing-schizophrenia-drug-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 11:00:00,2024-11-11T11:00:00-05:00,2024-11-11,Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial,Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.,marketwatch.com,https://www.marketwatch.com/story/bristol-myers-squibbs-stock-soars-after-rival-abbvie-reports-disappointing-schizophrenia-drug-trial-e18c14a0,https://images.financialmodelingprep.com/news/bristol-myers-squibbs-stock-soars-after-rival-abbvie-reports-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 10:27:31,2024-11-11T10:27:31-05:00,2024-11-11,"AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges","On Monday, AbbVie Inc ABBV stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia.",benzinga.com,https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges,https://images.financialmodelingprep.com/news/abbvie-stock-slips-as-9-billion-schizophrenia-studies-flunk-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 09:25:00,2024-11-11T09:25:00-05:00,2024-11-11,AbbVie Stock Falls Sharply as Schizophrenia Therapy Shows No ‘Significant' Improvement,Two trials of the company's experimental schizophrenia drug show no significant improvement in symptoms.,barrons.com,https://www.barrons.com/articles/abbvie-stock-schizophrenia-therapy-eacb68ac,https://images.financialmodelingprep.com/news/abbvie-stock-falls-sharply-as-schizophrenia-therapy-shows-no-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 08:44:58,2024-11-11T08:44:58-05:00,2024-11-11,AbbVie's schizophrenia drug misses main goals of two trials,"AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its shares down more than 11% in premarket trading.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-schizophrenia-drug-misses-main-goals-two-trials-2024-11-11/,https://images.financialmodelingprep.com/news/abbvies-schizophrenia-drug-misses-main-goals-of-two-trials-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-11 08:30:00,2024-11-11T08:30:00-05:00,2024-11-11,AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia,"EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO, Ill. , Nov. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-provides-update-on-phase-2-results-for-emraclidine-in-schizophrenia-302301190.html,https://images.financialmodelingprep.com/news/abbvie-provides-update-on-phase-2-results-for-emraclidine-20241111.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-12 13:52:44,2024-11-12T13:52:44-05:00,2024-11-12,AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio,"On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.",benzinga.com,https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio,https://images.financialmodelingprep.com/news/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-20241112.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-12 11:36:07,2024-11-12T11:36:07-05:00,2024-11-12,AbbVie's loss is Bristol Myers Squibb's gain - analyst,"Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed. AbbVie stock took a $38 billion hit on Monday after the company revealed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1060443,https://images.financialmodelingprep.com/news/abbvies-loss-is-bristol-myers-squibbs-gain-analyst-20241112.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-12 10:31:30,2024-11-12T10:31:30-05:00,2024-11-12,"AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains",ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.,zacks.com,https://www.zacks.com/stock/news/2368841/abbvie-stock-declines-as-schizophrenia-studies-fail-bmy-gains?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2368841,https://images.financialmodelingprep.com/news/abbvie-stock-declines-as-schizophrenia-studies-fail-bmy-gains-20241112.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-12 08:53:00,2024-11-12T08:53:00-05:00,2024-11-12,"AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say","AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.",marketwatch.com,https://www.marketwatch.com/story/abbvies-disappointing-schizophrenia-drug-trial-bodes-well-forrival-bristol-myers-analysts-say-bd96e9c0,https://images.financialmodelingprep.com/news/abbvies-disappointing-schizophrenia-drug-trial-bodes-well-forrival-bristol-20241112.jpg
ABBV,2024-10-30,2024-10-16,2024-11-13,ABBV,,2024-11-12 07:14:56,2024-11-12T07:14:56-05:00,2024-11-12,"Buy, Sell, Or Hold AbbVie Stock?","AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired for around $9 billion earlier this year.",forbes.com,https://www.forbes.com/sites/greatspeculations/2024/11/12/buy-sell-or-hold-abbvie-stock/,https://images.financialmodelingprep.com/news/buy-sell-or-hold-abbvie-stock-20241112.jpg
